These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 32575027

  • 1. Orbital metastases from breast cancer: A retrospective analysis of 28 cases.
    Grajales-Alvarez R, Gutierrez-Mata A.
    Cancer Treat Res Commun; 2020; 24():100184. PubMed ID: 32575027
    [Abstract] [Full Text] [Related]

  • 2. Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival.
    Itani N, Grogan N, Mott S, Phadke S.
    Clin Breast Cancer; 2020 Jun; 20(3):209-214. PubMed ID: 32007466
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G, Guaineri A, Bianchi A, Amoroso V, Pasinetti N, Pasini M.
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [Abstract] [Full Text] [Related]

  • 4. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
    Ge QD, Lv N, Kong YN, Xie XH, He N, Xie XM, Wei WD.
    Asian Pac J Cancer Prev; 2012 Apr; 13(10):5081-6. PubMed ID: 23244114
    [Abstract] [Full Text] [Related]

  • 5. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
    Bai B, Yuan ZY, Liu DG, Teng XY, Wang SS.
    Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
    [Abstract] [Full Text] [Related]

  • 6. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM.
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
    Meisel JL, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X.
    Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
    [Abstract] [Full Text] [Related]

  • 8. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L, Cheng L, Zhu X, Gao Y, Fan L, Wang Z.
    BMC Cancer; 2021 Mar 06; 21(1):238. PubMed ID: 33676449
    [Abstract] [Full Text] [Related]

  • 9. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D, Zhou K.
    Clin Breast Cancer; 2020 Feb 06; 20(1):41-50.e8. PubMed ID: 31547956
    [Abstract] [Full Text] [Related]

  • 10. Orbital Metastases from Breast Cancer: Retrospective Analysis at an Academic Cancer Center.
    Pierson TM, Tebit EV, El Sayed A, Smolkin ME, Dillon PM.
    Breast J; 2016 Jul 06; 22(4):447-50. PubMed ID: 27143519
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L, Pistelli M, Merloni F, Fontana A, Bertolini I, De Angelis C, Bastianelli L, Della Mora A, Santinelli A, Savini A, Maccaroni E, Diodati L, Falcone A, Berardi R.
    Clin Breast Cancer; 2020 Feb 06; 20(1):e89-e98. PubMed ID: 31378534
    [Abstract] [Full Text] [Related]

  • 13. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
    Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, Vanlemmens L, Leheurteur M, Lévy C, Laborde L, Uwer L, D'hondt V, Berchery D, Lorgis V, Ferrero JM, Perrocheau G, Courtinard C, Mouret-Reynier MA, Velten M, Breton M, Parent D, Chabaud S, Robain M, Bachelot T.
    Eur J Cancer; 2019 Sep 06; 118():131-141. PubMed ID: 31330488
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
    Kuba S, Ishida M, Nakamura Y, Yamanouchi K, Minami S, Taguchi K, Eguchi S, Ohno S.
    Jpn J Clin Oncol; 2014 Nov 06; 44(11):1025-31. PubMed ID: 25156682
    [Abstract] [Full Text] [Related]

  • 17. Breast carcinoma subtypes show different patterns of metastatic behavior.
    Molnár IA, Molnár BÁ, Vízkeleti L, Fekete K, Tamás J, Deák P, Szundi C, Székely B, Moldvay J, Vári-Kakas S, Szász MA, Ács B, Kulka J, Tőkés AM.
    Virchows Arch; 2017 Mar 06; 470(3):275-283. PubMed ID: 28101678
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
    Ben Abdelkrim S, Fathallah K, Rouatbi R, Ayachi M, Hmissa S, Mokni M.
    Pathol Oncol Res; 2015 Jul 06; 21(3):553-61. PubMed ID: 25962349
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.